Treatment of inflammatory bowel diseases: To heal the wound or to heal the sick?

Journal of Crohn's and Colitis

Volumn 6, Issue 5, 2012, Pages 621-625

  Caprilli, Renzo ^a   Latella, Giovanni ^b   Frieri, Giuseppe ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Crohn's disease; IBD; Mucosal healing; Treatment; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; INFLIXIMAB; MESALAZINE; PLACEBO; SALAZOSULFAPYRIDINE;

ARTICLE; BIOLOGICAL THERAPY; CANCER RISK; COLON RESECTION; COLONOSCOPY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPIC THERAPY; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT RESPONSE; ULCER HEALING; ULCERATIVE COLITIS;

COMBINED MODALITY THERAPY; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; INTESTINES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84860835848     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.02.009     Document Type: Article

References (41)

1. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521.
2. Geboes K. Histopathology of Crohn's disease and ulcerative colitis. Inflammatory Bowel Diseases 2003, 255-276. Churchill-Livingstone, New York. 4 ed. J. Satsangi, L.R. Sutherland (Eds.).
3. Moser G. How often do patients with IBD have symptom recurrence?. Inflamm Bowel Dis 2008, 14:S47.
4. Odze R., Antonioli D., Peppercorn M., Goldman H. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 1993, 17:869-875.
5. Modigliani R., Mary J.Y., Simon J.F., Cortot A., Soule J.C., Gendre J.P., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811-818.
6. Kozarek R.A., Patterson D.J., Gelfand M.D., Botoman V.A., Ball T.J., Wilske K.R. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989, 110:353-356.
7. D'Haens G., Geboes K., Ponette E., Penninckx F., Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997, 112:1475-1481.
8. Sandborn W.J., Van O.E., Zins B.J., Tremaine W.J., Mays D.C., Lipsky J.J. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995, 109:1808-1817.
9. van Dullemen H.M., van Deventer S.J., Hommes D.W., Bijl H.A., Jansen J., Tytgat G.N., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129-135.
10. D'Haens G., Van D.S., Van H.R., Chalmers D., Kothe C., Baert F., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116:1029-1034.
11. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
12. Lichtenstein G.R., Ramsey D., Rubin D.T. Randomised clinical trial: delayed-release oral mesalazine 4.8g/day vs. 2.4g/day in endoscopic mucosal healing - ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011, 33:672-678.
13. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983-989.
14. Baron J.H., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964, 1:89-92.
15. Lennard-Jones J.E. Defining ulcer depth in colitis. Lancet 1996, 347:1731-1735.
16. Allez M., Lemann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol 2010, 16:2626-2632.
17. Rutter M.D., Saunders B.P., Wilkinson K.H., Rumbles S., Schofield G., Kamm M.A., et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004, 53:1813-1816.
18. D'Haens G., Sandborn W.J., Feagan B.G., Geboes K., Hanauer S.B., Irvine E.J., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
19. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
20. Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., Bianchi P.G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47-53.
21. Paoluzi O.A., Pica R., Marcheggiano A., Crispino P., Iacopini F., Iannoni C., et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002, 16:1751-1759.
22. Pineton de Chambrun G., Peyrin-Biroulet L., Lemann M., Colombel J.F. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010, 7:15-29.
23. Hanauer S.B., Kamm M.A., Diebold R., Barrett K., Joseph R.E. Long-term remission rates in patients with mild-to-moderate ulcerative colitis who require an MMX™ mesalamine dose increase to induce initial remission. Am J Gastroenterol 2007, 102. Abstract 614.
24. Marshall J.K., Irvine E.J. Rectal corticosteriods versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997, 40:775-781.
25. Kamm M.A., Sandborn W.J., Gassull M., Schreiber S., Jackowski L., Butler T., et al. Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007, 132:66-75.
26. Kruis W., Kiudelis G., Racz I., Gorelov I.A., Pokrotnieks J., Horynski M., et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009, 58:233-240.
27. Sandborn W.J., Kamm M.A., Lichtenstein G.R., Lyne A., Butler T., Joseph R.E. Multi Matrix System (MMX®) mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007, 26:205-215.
28. Ardizzone S., Cassinotti A., Duca P., Mazzali C., Penati C., Manes G., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011, 9:483-489.
29. Rubin D.T. We once were blind and now we see: is it time to treat ulcerative colitis to achieve mucosal healing?. Clin Gastroenterol Hepatol 2011, 9:456-457.
30. Reinisch W., Sandborn W.J., Hommes D.W., D'Haens G., Hanauer S., Schreiber S., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011, 60:780-787.
31. Ochsenkuhn T., D'Haens G. Current misunderstandings in the management of ulcerative colitis. Gut 2011, 60:1294-1299.
32. Rutter M., Saunders B., Wilkinson K., Rumbles S., Schofield G., Kamm M., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
33. Peyrin-Biroulet L., Ferrante M., Magro F., Campbell S., Franchimont D., Fidder H., et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011, 5:477-483.
34. Cellier C., Sahmoud T., Froguel E., Adenis A., Belaiche J., Bretagne J.F., et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994, 35:231-235.
35. Allez M., Lemann M., Bonnet J., Cattan P., Jian R., Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002, 97:947-953.
36. Rutgeerts P., Diamond R.H., Bala M., Olson A., Lichtenstein G.R., Bao W., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442.
37. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
38. Laharie D., Reffet A., Bellennée G., Chabrun E., Subtil C., Razaire S., et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther 2011, 33:714-721.
39. Bouguen G., Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk?. Gut 2011, 60:1178-1181.
40. Latella G., Caprilli R., Travis S. In favour of early surgery in Crohn's disease: a hypothesis to be tested. J Crohns Colitis 2011, 5:1-4.
41. Hopkins R.J., Girardi L.S., Turney E.A. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996, 110:1244-1252.